NLS Pharmaceutics Gains Japan Patent for Mazindol ER in Heroin Dependence Treatment

ZURICH, SWITZERLAND / ACCESSWIRE / October 21, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW), a biopharmaceutical company based in Switzerland, has announced the approval of its Japanese patent application No. 2020-513594. This patent pertains to the utilization of Mazindol ER (extended-release) for treating heroin addiction, introducing a new method for tackling opioid use disorder.

Alex Zwyer, CEO of NLS, emphasized the significance of developing mazindol as a treatment for substance use disorder, noting the potential it holds for individuals struggling with addiction. He highlighted the company's dedication to pioneering therapeutic solutions to meet substantial medical needs.

### Major Points of the Patent
#### Mazindol ER for Heroin Addiction
Mazindol, a compound with unique pharmacological attributes, has demonstrated promising in vivo results in curbing heroin addiction. It functions by modulating neurotransmitter systems involved in reward mechanisms and addiction pathways. The patent ensures protection for the use of Mazindol ER specifically against opioid addiction, targeting heroin, known for its high potency and addictiveness.

#### Mechanism of Action
Unlike conventional opioid treatments, Mazindol doesn't act as a direct agonist or antagonist. Instead, it indirectly influences the brain's reward systems by targeting opioid receptors such as μ-opioid, κ-opioid, and δ-opioid receptors. By affecting these receptors, Mazindol helps in reducing cravings and compulsive drug-seeking behavior, diminishing the risk of dependence that comes with other treatments.

#### Emphasis on Long-Term Effectiveness
The patent includes claims for a sustained-release formulation of Mazindol, which enables a consistent release of the drug over extended periods. This formulation aids in improving patient adherence and lessening the chances of relapse. By maintaining therapeutic drug levels in the bloodstream for a longer duration, this extended-release version provides more stable symptom management for those recovering from heroin addiction.

### Scientific Background
Opioid Use Disorder (OUD), particularly heroin addiction, is a major global health concern. Heroin creates a strong bond with brain receptors, causing intense euphoria followed by physical dependency and withdrawal symptoms. Traditional treatment methods usually involve opioid substitution therapies, which have their own dependency risks. Mazindol offers a non-opioid alternative by targeting the brain's addiction circuits, potentially lowering the risk of relapse and enhancing recovery outcomes.

Mazindol's unique effectiveness in treating heroin addiction stems from its ability to regulate the meso-corticolimbic system, which comprises key areas in the brain's reward circuitry like the ventral tegmental area (VTA) and nucleus accumbens. By normalizing these pathways, Mazindol helps reduce the compulsive behaviors tied to opioid use disorder, offering new hope for those battling heroin dependency.

### Japanese Patent Approval
NLS Pharmaceutics successfully appealed the initial rejection of its patent application, receiving a favorable verdict from the Japan Patent Office (JPO) on October 2, 2024. This granted patent, with eight claims, offers robust protection for Mazindol ER and its specific application in treating opioid addiction, particularly heroin dependence. This outcome signifies an innovative step in addiction medicine and positions Mazindol ER as a potentially groundbreaking treatment for heroin addiction in Japan and other regions.

### About NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd. is an international development-stage biopharmaceutical company collaborating with renowned scientists and top-tier partners to create novel therapies for rare and complex central nervous system disorders. Founded in 2015 and headquartered in Switzerland, NLS is managed by a team with a proven track record in successfully developing and commercializing product candidates.